secwatch / observer
8-K filed June 2, 2023, 7:59 PM ET ticker APVO CIK 0001671584
other confidence high sentiment neutral materiality 0.15

Aptevo shareholders elect Harsanyi and Kunz to board, ratify Moss Adams as auditor

Aptevo Therapeutics Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aptevo Therapeutics Inc. shareholders approved Election of Directors at the 2023-06-02 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-02
Exact text from the filing
The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes: FOR WITHHELD BROKER NON-VOTES Zsolt Harsanyi, Ph.D. 967,133 343,098 2,566,806 Barbara Lopez Kunz 716,175 594,056 2,566,806
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aptevo Therapeutics Inc. shareholders approved Approval, on a non-binding advisory basis, of the Company's named executive officer compensation as disclosed in the Proxy Statement at the 2023-06-02 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-06-02
Exact text from the filing
FOR AGAINST ABSTAIN BROKER NON-VOTES 969,344 332,792 8,095 2,566,806
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Aptevo Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm for 2023 at the 2023-06-02 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-02
Exact text from the filing
FOR AGAINST ABSTAIN 3,581,428 276,500 19,109
View on SEC.gov

Browse all shareholder votes →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR
accession 0000950170-23-026092
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.